A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma

被引:0
|
作者
Ikeda, Masafumi [1 ]
Sung, Max W. [2 ]
Kudo, Masatoshi [3 ]
Kobayashi, Masahiro [4 ]
Baron, Ari D. [5 ]
Finn, Richard S. [6 ]
Kaneko, Shuichi [7 ]
Zhu, Andrew X. [8 ]
Kubota, Tomoki [9 ]
Kraljevic, Silvija [10 ]
Ishikawa, Kohei [9 ]
Siegel, Abby B. [11 ]
Kumada, Hiromitsu [4 ]
Young, Louise [12 ]
Okusaka, Takuji [13 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
[2] Tisch Canc Inst Mt Sinai, New York, NY USA
[3] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[4] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan
[5] Pacific Hematol Oncol Associates, Calif Pacific Med Ctr, San Francisco, CA USA
[6] UCLA Med Ctr, David Geffen Sch Med, Losa Angeles, CA USA
[7] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan
[8] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA
[9] Eisai & Co Ltd, Tokyo, Japan
[10] Eisai Ltd, Hatfield, Herts, England
[11] Merck Co Inc, Kenilworth, NJ USA
[12] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[13] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
182
引用
收藏
页码:105 / 105
页数:1
相关论文
共 50 条
  • [31] A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
    Makker, Vicky
    Rasco, Drew W.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Li, Di
    Schmidt, Emmett V.
    Shumaker, Robert Charles
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Phase 1b study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Evaluating the immunological effects.
    Kojima, Takashi
    Shinohara, Hajime
    Eguchi, Susumu
    Izawa, Naoki
    Chin, Keisho
    Tanaka, Yoshihiro
    Machida, Nozomu
    Iwatsuki, Masaaki
    Iijima, Katsunori
    Horita, Yosuke
    Satoh, Taroh
    Ojima, Hitoshi
    Mitani, Seiichiro
    Nishino, Kazumi
    Hirai, Hiroshi
    Mizutani, Hiroya
    Chisamore, Michael Jon
    Minashi, Keiko
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 477 - 477
  • [33] Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
    Finn, Richard S.
    Qin, Shukui
    Piscaglia, Fabio
    Evans, Thomas R. Jeffry
    Knox, Jennifer J.
    Lopez Lopez, Carlos
    Ramji, Zahra
    Ren, Min
    Mody, Kalgi
    Vogel, Arndt
    Kudo, Masatoshi
    LIVER CANCER, 2024, 13 (05) : 537 - 547
  • [34] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [35] Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress
    Li, D.
    Cheng, A.
    Lim, H.
    Llovet, J.
    Zhu, Y.
    Hatogai, K.
    Siegel, A.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S144 - S145
  • [36] Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
    Rimini, Margherita
    Persano, Mara
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Salani, Francesca
    Lonardi, Sara
    Piscaglia, Fabio
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Schirripa, Marta
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7565 - 7577
  • [37] Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
    Margherita Rimini
    Mara Persano
    Toshifumi Tada
    Goki Suda
    Shigeo Shimose
    Masatoshi Kudo
    Jaekyung Cheon
    Fabian Finkelmeier
    Ho Yeong Lim
    José Presa
    Francesca Salani
    Sara Lonardi
    Fabio Piscaglia
    Takashi Kumada
    Naoya Sakamoto
    Hideki Iwamoto
    Tomoko Aoki
    Hong Jae Chon
    Vera Himmelsbach
    Marta Schirripa
    Margarida Montes
    Caterina Vivaldi
    Caterina Soldà
    Atsushi Hiraoka
    Takuya Sho
    Takashi Niizeki
    Naoshi Nishida
    Christoph Steup
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Satoshi Yasuda
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Satoru Kakizaki
    Noritomo Shimada
    Kazuhito Kawata
    Fujimasa Tada
    Hideko Ohama
    Kazuhiro Nouso
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7565 - 7577
  • [38] Lenvatinib as a therapy for unresectable hepatocellular carcinoma
    Spallanzani, Andrea
    Orsi, Giulia
    Andrikou, Kalliopi
    Gelsomino, Fabio
    Rimini, Margherita
    Riggi, Laura
    Cascinu, Stefano
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (11) : 1069 - 1076
  • [39] Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population
    Fujiwara, Ryo
    Yuasa, Takeshi
    Kobayashi, Kenichi
    Yoshida, Tetsuya
    Kageyama, Susumu
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (05) : 461 - 469
  • [40] Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
    Song Chen
    Zhiqiang Wu
    Feng Shi
    Qicong Mai
    Liguang Wang
    Fan Wang
    Wenquan Zhuang
    Xiaoming Chen
    Huanwei Chen
    Bo Xu
    Jiaming Lai
    Wenbo Guo
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2115 - 2125